Literature DB >> 2954713

Medroxyprogesterone acetate plasma pharmacokinetics after intravenous administration in rabbits.

F Pannuti, C M Camaggi, E Strocchi, R Comparsi.   

Abstract

Medroxyprogesterone acetate (MAP) plasma pharmacokinetics was followed up in a total of 30 New Zealand rabbits after i.v. administration (0.1, 0.5, and 1.0 mg/kg) of either an aqueous suspension or a homogeneous solution of the drug in dimethylsulphoxide (DMSO). A well-defined triphasic decay of MAP plasma levels was noticeable in the animals treated with DMSO solutions. A delayed concentration peak was often present when aqueous suspensions were used, so if is not feasible to fit the experiment with simple polyexponential equations. Model-independent pharmacokinetic analysis (statistical moment theory) revealed a significant dependence of plasma clearance and mean residence time on the dose administered in both conditions.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2954713     DOI: 10.1007/bf00261479

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  3 in total

1.  Medroxyprogesterone acetate (MAP) relative bioavailability after single high-dose administration in cancer patients.

Authors:  F Pannuti; C M Camaggi; E Strocchi; M Giovannini; A R Di Marco; B Costanti
Journal:  Cancer Treat Rep       Date:  1982-12

2.  Medroxyprogesterone acetate (MAP) plasma levels after multiple high-dose administration in advanced cancer patients.

Authors:  C M Camaggi; E Strocchi; M Giovannini; B Angelelli; B Costanti; E Zebini; P Ferrari; F Pannuti
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

3.  Medroxyprogesterone acetate bioavailability after high-dose intraperitoneal administration in advanced cancer.

Authors:  C M Camaggi; E Strocchi; B Costanti; P Beghelli; P Ferrari; F Pannuti
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.